Related Experiment Video
Updated: Apr 5, 2026
MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data
Published on: February 7, 2025
Genome-wide profiling identifies the genetic dependencies of cell death following EGFR inhibition
Sydney A Porto1, Gavin A Birdsall1, Nicholas W Harper1
1Department of Systems Biology, UMass Chan Medical School, Worcester, Massachusetts, USA.
Abstract:
EGFR is a proto-oncogene that is mutationally activated in a variety of cancers. Small molecule inhibitors targeting EGFR can effectively slow the progression of disease, and in some settings, these drugs even cause dramatic tumor regression. However, responses to EGFR inhibitors are rarely durable, and the mechanisms contributing to response variation remain unclear. In particular, several distinct mechanisms have been proposed to explain how EGFR inhibition activates cell death, and a consensus has yet to emerge. In this study, we use functional genomics with specialized analyses to infer how genetic perturbations affect the drug-induced death rate. Our data clarify that inhibition of PI3K signaling drives the lethality of EGFR inhibition. Inhibition of other pathways downstream of EGFR, including the RAS-MAPK pathway, promotes growth suppression but not the lethal effects of EGFR inhibitors. Taken together, our study provides a "reference map" for the genome-wide genetic dependencies of lethality in response to EGFR inhibitors.
Insights
Targeting the Epidermal Growth Factor Receptor (EGFR) with inhibitors slows cancer growth. Our study reveals that inhibiting PI3K signaling is key to the lethal effects of EGFR inhibitors, not RAS-MAPK.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genomics
Background:
- Epidermal Growth Factor Receptor (EGFR) is a proto-oncogene frequently activated in various cancers.
- EGFR inhibitors offer therapeutic benefits, but response durability and mechanisms of cell death remain unclear.
- Understanding resistance mechanisms is crucial for improving cancer treatment efficacy.
Purpose of the Study:
- To elucidate the genetic dependencies governing lethality induced by EGFR inhibitors.
- To differentiate pathways mediating cell death versus growth suppression upon EGFR inhibition.
- To create a comprehensive map of genome-wide dependencies for EGFR inhibitor lethality.
Main Methods:
- Utilized functional genomics screens to assess the impact of genetic perturbations on drug-induced death rates.
- Performed specialized analyses to infer causal relationships between genetic alterations and cellular response.
- Investigated the roles of key downstream signaling pathways, including PI3K and RAS-MAPK.
Main Results:
- Demonstrated that inhibition of Phosphatidylinositol 3-Kinase (PI3K) signaling is the primary driver of lethality caused by EGFR inhibition.
- Showed that other EGFR downstream pathways, such as RAS-MAPK, contribute to growth suppression but not cell death.
- Identified specific genetic dependencies that dictate sensitivity or resistance to EGFR inhibitors.
Conclusions:
- PI3K pathway inhibition is essential for the cytotoxic effects of EGFR inhibitors.
- RAS-MAPK pathway activation mediates cytostatic rather than cytotoxic responses to EGFR inhibition.
- The study provides a foundational 'reference map' for understanding EGFR inhibitor lethality across the genome.
